Today Iterum Therapeutics Plc – Ordinary Share (NASDAQ:ITRM) Reported Decrease in Shorted Shares

The stock of Iterum Therapeutics Plc – Ordinary Share (NASDAQ:ITRM) registered a decrease of 21.17% in short interest. ITRM’s total short interest was 32,400 shares in September as published by FINRA. Its down 21.17% from 41,100 shares, reported previously. With 7,300 shares average volume, it will take short sellers 4 days to cover their ITRM’s short positions. The short interest to Iterum Therapeutics Plc – Ordinary Share’s float is 0.75%.

The stock decreased 7.41% or $0.5 during the last trading session, reaching $6.25. About 619 shares traded. Iterum Therapeutics plc (NASDAQ:ITRM) has declined 25.82% since September 13, 2018 and is downtrending. It has underperformed by 25.82% the S&P500.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company has market cap of $90.15 million. The firm is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. It currently has negative earnings.

More notable recent Iterum Therapeutics plc (NASDAQ:ITRM) news were published by: Globenewswire.com which released: “Iterum Therapeutics Receives QIDP for Oral and IV Sulopenem in Four Additional Indications as well as Fast Track Designation – GlobeNewswire” on March 19, 2019, also Seekingalpha.com with their article: “Your Daily Pharma Scoop: Recent IPO And Offerings Review – Seeking Alpha” published on May 31, 2018, Finance.Yahoo.com published: “Akorn to Present at the Jefferies 2019 Global Healthcare Conference – Yahoo Finance” on May 30, 2019. More interesting news about Iterum Therapeutics plc (NASDAQ:ITRM) were released by: Seekingalpha.com and their article: “Iterum Therapeutics up 27% on expanded QIDP status for sulopenem – Seeking Alpha” published on March 19, 2019 as well as Nasdaq.com‘s news article titled: “The 2018 IPO market’s most active venture capital firms – Nasdaq” with publication date: December 20, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.